Skip to main content

Palo Alto-based cancer test developer Guardant Health cuts 130 jobs

The move comes about a month after the company's stock dropped by about 30% when it reported trial results of a test for colorectal cancer that disappointed some of its investors.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.